|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University Hospital, Geneva |
|---|---|
| Information provided by: | University Hospital, Geneva |
| ClinicalTrials.gov Identifier: | NCT00403806 |
Purpose
Adeno-tonsillectomy is a commonly performed surgical procedure in children.Main morbidities are postoperative pain, nausea and vomiting, and haemorrhage.Non-steroidal anti-inflammatory drugs (NSAIDs)widely used for paincontrol increase the risk of postoperative bleeding and reoperation. Dexamethasone is an powerful antiemetic and has shown analgesic efficacy. Antiemetic and analgesic dose-response has never been established.
| Condition | Intervention | Phase |
|---|---|---|
|
Postoperative Nausea and Vomiting Postoperative Pain |
Drug: dexamethasone Drug: Dexamethasone Drug: Saline |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Antiemetic and Analgesic Efficacy and Safety of Dexamethasone for Paediatric Adeno-Tonsillectomy - A Randomised, Placebo-Controlled, Double-Blind, Dose-Finding Study |
| Enrollment: | 215 |
| Study Start Date: | February 2005 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
1: Active Comparator
Intravenous dexamethasone 0.05 mg per kg bodyweight
|
Drug: dexamethasone
intravenous dexamethasone 0.05 mg per kg bodyweight
|
|
2: Active Comparator
Intravenous dexamethasone 0.15 mg per kg bodyweight
|
Drug: Dexamethasone
Intravenous dexamethasone 0.15 mg per kg bodyweight
|
|
3: Active Comparator
Intravenous dexamethasone 0.5 mg per kg bodyweight
|
Drug: dexamethasone
Intravenous dexamethasone 0.5 mg per kg bodyweight
|
|
4: Placebo Comparator
Intravenous saline
|
Drug: Saline
Intravenous saline
|
Hide Detailed DescriptionRandomisation and blinding:Children will be randomised to one of four groups of equal size:
Group 1: Placebo NaCL 0.9%,Group 2:Dexa 0.05 mg/kg, Group 3: Dexa 0.15 mg/kg, Group 4:Dexa 0.5 mg/kg
Indistinguishable 20 ml ampoules will be prepared and randomised by the Hospital Pharmacy. Children will receive 0.5 ml/kg of the solution as an IV bolus after induction of anaesthesia. The maximum volume of dexamethasone injected will be limited to 20 ml (corresponding to a maximum dose of 20 mg in a child with ≥40 kg bodyweight).
Standardized Anesthesia technique and surgical procedure
5.1. Intraoperatively
5.2. Postoperatively
Follow up will be during the hospital stay, through a telephone interview 48 hours after surgery, and through a surgical control (standard procedure) at about one week. Preoperatively, parents and children will be instructed in the evaluation of pain. Parents will be given a questionnaire to be filled in twice daily (morning and evening) after discharge of the child, and to bring it back to the routine postoperative surgical control at one week (or to send it back by post).
Endpoint PONV
Endpoint pain intensity In hospitalised children, pain assessment will be with the revised Faces Pain Scale (FPS-r) [Hicks et al, 2001] and with the conventional 0-10 cm Visual Analogue Scale (VAS). The FPS-r was adapted from the Faces Pain Scale [Bieri et al, 1990] in order to make it possible to score on the widely accepted 0-10 point metric. It shows a close linear relationship with the visual analogue pain scale across the age range from 4 to 16 years. In the case that a younger child is not able to express adequately its pain with the FPS-r or with the VAS we will use the CHEOP Scale (Children of Eastern Ontario Pain Scale); this is a behavioural observation scale [McGrath et al,1985]. Pain will be evaluated at arriving in the PACU, 1-hourly during the PACU stay, 4-hourly on the ward, and twice daily after discharge (see questionnaire). Sleeping children will not be woken up.
Cumulative doses per day of paracetamol/codeine and of any other analgesic (NSAIDs, opioids) will be recorded.
Further endpoints
Adverse effects, safety
Eligibility| Ages Eligible for Study: | 3 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
Contacts and Locations| Switzerland, Canton of Geneva | |
| University Hospital of Geneva, Anesthesia Department | |
| Geneva, Canton of Geneva, Switzerland, 1211 | |
| Principal Investigator: | Christoph A Czarnetzki, MD, MBA | Anesthesia Department |
| Study Chair: | Martin Tramer, MD, PhD | Anesthesia Department |
More Information
| Responsible Party: | University Hospital, Geneva ( Christoph Czarnetzki MD ) |
| Study ID Numbers: | NAC 04-005, Swissmedic DR 3028 |
| Study First Received: | November 24, 2006 |
| Last Updated: | January 22, 2009 |
| ClinicalTrials.gov Identifier: | NCT00403806 History of Changes |
| Health Authority: | Switzerland: Swissmedic |
|
Adenotonsillectomy Pediatrics Postoperative Nausea and Vomiting Pain |
Oral intake Dexamethasone Dose finding |
|
Dexamethasone Anti-Inflammatory Agents Vomiting Signs and Symptoms, Digestive Antineoplastic Agents Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Pain Hormones Signs and Symptoms Pathologic Processes Therapeutic Uses |
Nausea Dexamethasone acetate Pain, Postoperative Postoperative Nausea and Vomiting Antineoplastic Agents, Hormonal Gastrointestinal Agents Glucocorticoids Pharmacologic Actions Postoperative Complications Autonomic Agents Peripheral Nervous System Agents Central Nervous System Agents |